Form 4: Zenas BioPharma Director Granted Stock Options, Vesting in 2026

A recent SEC Form 4 filing reveals that Tomas Kiselak, a director of Zenas BioPharma, Inc. and Managing Member of Fairmount Funds Management LLC, was granted 18,500 stock options with an exercise price of $11.94, vesting fully on June 10, 2026.

Summary

• Tomas Kiselak, a director of Zenas BioPharma, Inc. (ZBIO), was granted 18,500 stock options on June 10, 2025.
• The options have an exercise price of $11.94 per share and are exercisable for 18,500 shares of common stock.
• The options are set to expire on June 10, 2035.
• The entire grant of 18,500 options will vest 100% on June 10, 2026, which marks the first anniversary of the vesting commencement date, subject to Mr. Kiselak's continued service.
• Mr. Kiselak holds these options for one or more investment vehicles managed by Fairmount Funds Management LLC and is obligated to transfer any net cash or stock received from the option to Fairmount for the benefit of such funds.
• Both Mr. Kiselak and Fairmount disclaim beneficial ownership of the options and underlying common stock, except to the extent of Fairmount's pecuniary interest.
• Fairmount Funds Management LLC and Fairmount Healthcare Fund II L.P. are considered directors by deputization of Zenas BioPharma due to Tomas Kiselak's role on the board and as a Managing Member of Fairmount.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns the director's interests with shareholders and incentivizes long-term performance. It's a standard compensation practice and doesn't indicate any negative operational or financial issues.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedule encourages continued service and commitment from the director, fostering stability in governance.

Negatives

• No explicit negatives are present in this Form 4 filing, as it details a routine equity compensation event.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The stock options are set to vest 100% on June 10, 2026, contingent on the director's continued service, indicating a future milestone for the equity compensation and a continued alignment of interests.

Management Comments

• "Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount Funds Management LLC ('Fairmount' and each such investment vehicle, a 'Fairmount Fund')."
• "Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund."
• "Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock."
• "Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."
• "Fairmount and Fairmount Healthcare Fund II L.P. may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount."

Industry Context

This Form 4 filing details an equity compensation event for a director at Zenas BioPharma, Inc., a biopharmaceutical company. Such grants are standard practice across industries, including biotech, to attract and retain talent and align interests, but this specific filing does not provide broader industry trend analysis.

Comparison to Industry Standards

• The granting of stock options to directors is a common practice in the biopharmaceutical industry and broader corporate governance to incentivize long-term performance and align interests with shareholders.
• The exercise price of $11.94 would typically be the closing price of ZBIO common stock on the grant date, which is standard for non-qualified stock options.
• A one-year cliff vesting schedule (100% vesting after one year) is a common, though not universal, vesting approach for director equity grants, balancing immediate incentive with retention.

Management Changes

Corporate Governance

Related Party Transactions

• The stock option grant to Tomas Kiselak, a director, is considered a related party transaction.
• The arrangement where Mr. Kiselak holds the option for investment vehicles managed by Fairmount Funds Management LLC, and is obligated to turn over proceeds to Fairmount, further clarifies the related party nature of the transaction.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's interests with shareholders, potentially leading to better long-term performance. However, it also represents potential future dilution if options are exercised.
• Management/Directors: Provides a significant incentive for Tomas Kiselak to remain engaged and contribute to the company's success.

Next Steps

• Continued service of Tomas Kiselak as a director of Zenas BioPharma, Inc.
• Vesting of the 18,500 stock options on June 10, 2026, subject to continued service.
• Potential exercise of the stock options by Tomas Kiselak (on behalf of Fairmount investment vehicles) at or after the vesting date and before the expiration date.

Key Dates

Recommendation

Keywords

Zenas BioPharma, ZBIO, Stock Options, SEC Form 4, Director Compensation, Fairmount Funds Management, Tomas Kiselak, Equity Grant, Beneficial Ownership